Located in Vancouver, British Columbia, Tekmira is focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Today, Tekmira took a major step towards prominence with the announcement that its Investigational New Drug (NYSE:IND) application for TKM-Ebola has been approved by the United States Food and Drug Administration (FDA) allowing Tekmira to initiate a Phase 1 clinical trial.
Tekmira is developing TKM-Ebola, a systemically delivered RNAi therapeutic that utilizes Tekmira’s lipid nanoparticle (LNP) delivery technology for the treatment of Ebola virus infection. Currently, there are no approved treatments for Ebola or other hemorrhagic fever viruses. With this approval, Tekmira has an opportunity to become a pioneer within the sector.
Leading the way at Tekmira is Dr. Mark J. Murray whom serves as the company’s President and CEO. In reference to this press release, Dr. Murray stated, “We are pleased to have received the FDA’s approval of our TKM-Ebola IND. With this approval, we remain on track to achieve another significant milestone for the company by initiating the Phase 1 clinical trial of this product in early 2012.” Dr. Murray further added, “TKM-Ebola is being developed under a $140 million contract awarded to us by the U.S. Government’s Transformational Medical Technologies (TMT) Program. We look forward to continuing this successful collaboration to drive the TKM-Ebola program forward in clinical development.”
Currently, Tekmira is trading in the in the $1.45 range. To learn more about this press release or the company as a whole, visit the company’s corporate website at www.tekmirapharm.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html